small molecule

VIVJOA

OTESECONAZOLE

Loss of exclusivityMarch 2036latest FDA-listed patent expiry

CompanyMycovia Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	VIVJOA
Active ingredient	OTESECONAZOLE
Strength	150MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	April 2022
Marketing status	RX

Listed patents

Patent	Expires	Type
9840492	March 2036	substance, product
10414751	March 2036	substance, product
11247981	May 2033	use U-3366
8754227	April 2031	use U-3366
8236962	April 2031	substance, product

Regulatory exclusivity

Code	Expires
GAIN	April 2032
NCE	April 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.